Meeting Overview - The second board meeting of King Kai (Liaoning) Life Science Co., Ltd. was held on August 22, 2025, with all 7 directors present, including 2 via communication [1] - The meeting was chaired by Chairman Fumin Wang and complied with relevant laws and regulations [1] Financial Reporting - The board approved the 2025 semi-annual report, confirming it accurately reflects the company's financial status and operational results without any misleading statements [2] - The report on the management and use of raised funds was also approved, indicating compliance with regulations and accurate reporting [2] Compensation Adjustments - The board agreed to adjust the independent director's allowance from 100,000 yuan to 120,000 yuan per year, effective upon shareholder approval [3] Fund Management - The board approved a change in the method of using raised funds from loans to capital injection into subsidiaries, aimed at improving fund efficiency and protecting shareholder interests [3] - The use of idle raised funds for cash management was also approved, ensuring it does not affect project construction or normal operations [5] Governance Enhancements - The board approved revisions to the company's articles of association and internal governance rules to enhance corporate governance and protect investor rights [6][7] - New internal governance systems were established to further improve the company's governance structure [9] Capital Injection - The board approved the use of self-owned funds to increase capital in Kingchem Life Science LLC for the construction of Kingchem Laboratories Inc., supporting the company's international competitiveness [10] Upcoming Meetings - The company plans to hold its first temporary shareholders' meeting on September 22, 2025, combining on-site and online voting [10]
金凯生科: 董事会决议公告